Ocular Surface Alteration after Long-term Treatment with an Antiglaucomatous Drug

Herreras, José M.; Pastor, J. Carlos; Calonge, Margarita; Asensio, Victor M.

doi:10.1016/s0161-6420(92)31847-0

Cited by 212 publications

(125 citation statements)

References 23 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…Even in low concentrations BAK can trigger apoptosis in human corneal and conjunctival epithelial cells and it can cause chronic stromal inflammation [23][24][25]. As a detergent, it disrupts the tear film after only a single drop [26] and with the chronic use decreases the density of goblet cells in the conjunctival epithelium [27] which are producing mucous layer of the tear film. In addition, it has a detergent effect on corneal barrier function by breaking down the intercellular adhesion which makes the tear film unstable and unable to maintain the healthy ocular surface [28].…”

Section: Discussionmentioning

confidence: 99%

Prevalence of Ocular Surface Disease in Patients with Glaucoma using Topical Antiglaucoma Medications

Barišić¹

2014

J Clin Exp Ophthalmol

View full text Add to dashboard Cite

Purpose: To establish the prevalence of ocular surface disease (OSD) in glaucoma patients using topical intraocular pressure-lowering (IOP) therapy and to compare the frequency and severity of symptoms with the control group of normal subjects. Methods:This prospective, multicenter, observational study included patients with glaucoma in four different Departments of Ophthalmology. A matched group of normal subjects served as controls. For each patient we have collected detailed family history, clinical records and calculated ocular surface disease index (OSDI) scores (0-100), based on the information obtained from OSDI questionnaires. Results:In total, we have evaluated 160 patients. Of those, 110 were glaucoma patients and 50 were normal subjects. Among 110 glaucoma treated patients 83 (75%) had OSDI scores indicating mild to severe OSD. Among 50 patients without glaucoma 15 (30%) had OSDI score indicating mostly mild to moderate OSD. The severity of symptoms correlates with the number of IOP medications used and the duration of treatment. Conclusion:This study confirms the high prevalence of OSD in patients treated for glaucoma with topical IOP medications. The adverse effect of these agents can influence the compliance and successful treatment of glaucoma patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence of Ocular Surface Disease in Patients with Glaucoma using Topical Antiglaucoma Medications

Barišić¹

2014

J Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…17,18 Almost half of the patients experience symptoms of ocular irritation with their glaucoma medication. Side effects of antiglaucomatous drugs are real healthcare concern which decreases the compliance of patients to treatment.…”

Section: Discussionmentioning

confidence: 99%

“…They cause conjunctival hyperaemia, conjunctivitis, blepharitis, periorbital dermatitis, superficial punctate keratitis, pseudopemfigoid, contact allergy, and dry eye. [17][18][19][20][21] These drugs also decrease the stability of the precorneal tear film and worsen the pre-existing dry eye symptoms. 19 Ocular surface side effects of antiglaucomatous drugs are caused by either the drug itself or by preservatives.…”

Section: Discussionmentioning

confidence: 99%

The effect of artificial tear administration on visual field testing in patients with glaucoma and dry eye

Yenice

Temel

Örüm

2006

Eye

View full text Add to dashboard Cite

Aim To examine the effects of artificial tear administration on perimetry of primary open-angle glaucoma patients with dry eye. Methods A total of 40 patients with primary open-angle glaucoma experienced in automated perimetry with symptoms of dry eye were enrolled in this study. After their pretest visit, they were instructed to use artificial tear four times a day in both eyes for 1 week. After 1 week, patients had visual field testing. Test taking time, reliability parameters (false-positive and false-negative errors) visual field indices and number of depressed points at different probability levels (Po5%, Po2%, Po1%, Po0.5%) in both total and pattern deviation plots were compared using paired T test. Results We found significant improvement in reliability parameters (false-positive errors from 2.472.1 to 2.171.9, P ¼ 0.02; and false-negative errors from 7.376.4 to 4.873.6, P ¼ 0.01) and visual field indices (MD increased from 5.9775.61 to 4.5774.53, P ¼ 0.001; PSD from 4.6772.95 to 4.1372.77, P ¼ 0.04 and SF decreased from 2.2471.23 to 1.8370.77, P ¼ 0.04) in the second testing after artificial tear administration. Test time significantly increased from 11.6672.55 min to 14.2671.36, P ¼ 0.001. The number of depressed points at probability levels Po1% (P ¼ 0.03) and Po0.5% (P ¼ 0.04) at total deviation plot and Po2% (P ¼ 0.02) and Po0.5% (P ¼ 0.009) in pattern deviation plot decreased significantly. Conclusion Artificial tear administration in glaucomatous patients with dry eye seems to improve significantly reliability parameters and visual field indices.

show abstract

“…22,25,26 Another study reported that only 4.8% and 33.8% of patients on anti-glaucoma medications had TBUT and Schirmer's test values of 410 s and 410 mm, respectively, as compared with a healthy population of 100% above these thresholds. 27 We hypothesize that TFO may be raised in glaucoma patients, both on topical therapy and post trabeculectomy, compared with normal controls. This study is therefore aimed to compare TFO in chronically medicated glaucoma patients and post-trabeculectomy patients to controls without glaucoma or dry eyes.…”

Section: Introductionmentioning

confidence: 98%

Effect of chronic anti-glaucoma medications and trabeculectomy on tear osmolarity

Lee

Wong

Chua

et al. 2013

Eye

View full text Add to dashboard Cite

Purpose To evaluate the tear film osmolarity (TFO) and ocular surface clinical signs and symptoms in chronically medicated glaucoma patients and post-trabeculectomy patients. Methods This is a single-center, prospective case-controlled study. One-hundred and thirty eyes of 130 participants aged Z45 years were included (49 normal controls, 50 glaucoma patients on chronic preserved antiglaucoma medication Z6 months, and 31 post-trabeculectomy patients not on medication Z6 months). TFO, tear break-up time (TBUT), Schirmer's test I and dry eye symptoms were evaluated. Data from both groups of glaucoma patients were compared with age and sex-matched controls. Logistic regression was performed to calculate the odds ratios. Results Mean TFO in the three groups were 301.4 ± 7.7, 307.0 ± 9.3, and 307.4 ± 11.6 mOsm/l, respectively. Compared with normal controls, chronically medicated glaucoma patients and post-trabeculectomy patients were more likely to have a raised TFO, with odds ratios (95% CI) of 4.43 (1.74-11.32) and 2.76 (1.02-7.94), respectively. Both groups of glaucoma patients were also more likely to experience dry eye symptoms, with ORs of 4.72 (1.92-11.59) and 4.24 (1.54-11.72). There was no significant difference in TFO and symptoms between both groups of glaucoma patients, and in TBUT and Schirmer's test across all three groups. Conclusions Patients on chronic topical antiglaucoma medication and posttrabeculectomy patients were more likely to have raised TFO and dry eye symptoms, suggesting significant ocular surface disease. Glaucoma practitioners should be aware that dry eye symptoms and raised TFO may occur in the absence of TBUT and Schirmer's test abnormality.

show abstract

Ocular Surface Alteration after Long-term Treatment with an Antiglaucomatous Drug

Cited by 212 publications

References 23 publications

Prevalence of Ocular Surface Disease in Patients with Glaucoma using Topical Antiglaucoma Medications

Prevalence of Ocular Surface Disease in Patients with Glaucoma using Topical Antiglaucoma Medications

The effect of artificial tear administration on visual field testing in patients with glaucoma and dry eye

Effect of chronic anti-glaucoma medications and trabeculectomy on tear osmolarity

Contact Info

Product

Resources

About